Onesource Specialty Pharma cash flow

Latest FY26
Cash from operations
₹8.5cr−₹21.5 cr in FY25
Capital spending
₹569crNo figure a year before
Free cash flow
−₹561cr−₹21.5 cr in FY25
Cash from financing
₹359cr−81.9% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—279274
—0.00.1
—122166
—−11.715.8
—0.0−2.7
—2.74.3
—−19.00.0
—12.60.0
—−0.10.7
Changes in working capital
—−28144.0
—−190−257
—13.00.0
—0.0−74.9
—209−118
—−28.0−14.2
Cash from operating activities
−20.1−92.0−67.1
—10938.5
—17.3−28.5
—8.7−7.0
—8.5−21.5
Cash from investing activities
—5690.0
—0.0−124
—0.013.2
—74.1−90.6
—−495−201
Cash from financing activities
—5.7876
—704345
—207−631
—23.60.0
—119−157
—0.0−21.0
—3591,987
—−1271,765
—−1271,765
——165
Reference items
396304467
23.5%21.4%32.3%
−561−561−21.5
—−175—
−₹48.90−₹48.90−₹1.88
—−0.12×1.20×
—8.7−7.0
—119157
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ONESOURCE₹1,569.60

Onesource Specialty Pharma Ltd.

· Pharma & Health
₹ CrorePeersSTARDIVISLABGLANDPFIZERPOLYMEDRAINBOWKIMSJUBLPHARMAMcap ₹17,991 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation273.9279.1—
+ Impairment Loss / (Reversal)0.10.0—
+ Finance Costs166.3122.2—
+ Interest Income15.8-11.7—
+ Fair Value (Gains) / Losses-2.70.0—
+ Share-based Payments4.32.7—
+ Unrealised FX (Gain) / Loss0.0-19.0—
+ Other Non-cash Items0.012.6—
+ Other Reconciling Items0.7-0.1—
Changes in Working Capital
+ Inventories44.0-280.9—
+ Trade Receivables — Current-257.1-189.6—
+ Other Financial Assets — Current0.013.0—
+ Other Current Assets-74.90.0—
+ Trade Payables — Current-117.6208.9—
+ Other Current Liabilities-14.2-28.0—
Cash from Operating Activities
Profit Before Tax (per I/S)-67.1-92.0-20.1
+ Total Adjustments (incl. Working Capital)38.5109.2—
Cash from Operations (pre-tax)-28.517.3—
+ Income Taxes Paid-7.08.7—
Cash from Operating Activities-21.58.5—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)0.0569.1—
+ Disp of Fixed Assets-123.70.0—
+ Interest Received — Investing13.20.0—
+ Other Inflows / (Outflows) — Investing-90.674.1—
Cash from Investing Activities-201.1-495.0—
Cash from Financing Activities
+ Proceeds from Issue of Shares875.55.7—
+ Proceeds from Borrowings345.1703.8—
+ Repayment of Borrowings-631.0207.4—
+ Payment of Lease Liabilities0.023.6—
+ Interest Paid-156.5119.1—
+ Other Inflows / (Outflows) — Financing-21.00.0—
Cash from Financing Activities1,987.2359.4—
Net Changes in Cash (pre-FX)1,764.6-127.0—
Net Changes in Cash1,764.6-127.0—
Closing Cash165.4——
Reference Items
EBITDA466.5304.2395.9
EBITDA Margin %32.2921.4023.51
Free Cash Flow (CFO − Capex)-21.5-560.5-560.5
Free Cash Flow to Equity—-174.9—
Free Cash Flow per Basic Share-1.88-48.90-48.90
Cash Flow to Net Income1.20-0.12—
Cash Paid for Taxes-7.08.7—
Cash Paid for Interest156.5119.1—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.